Literature DB >> 21685022

GFR decline and mortality risk among patients with chronic kidney disease.

Robert M Perkins1, Ion D Bucaloiu, H Lester Kirchner, Nasrin Ashouian, James E Hartle, Taher Yahya.   

Abstract

BACKGROUND AND OBJECTIVES: Estimates of the effect of estimated GFR (eGFR) decline on mortality have focused on populations with normal kidney function, or have included limited information on factors previously shown to influence the risk of death among patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively assessed the effect of rate of eGFR decline on survival of patients with CKD receiving primary care through a large integrated health care system in central Pennsylvania between January 1, 2004, and December 31, 2009.
RESULTS: A total of 15,465 patients were followed for a median of 3.4 years. Median rates of eGFR change by those in the lower, middle, and upper tertiles of eGFR slope were -4.8, -0.6, and 3.5 ml/min per 1.73 m(2)/yr, respectively. In Cox proportional hazard modeling for time to death, adjusted for baseline proteinuria, changes in nutritional parameters, and episodes of acute kidney injury during follow-up (among other covariates), the hazard ratio for those in the lower (declining) and upper (increasing) eGFR tertiles (relative to the middle, or stable, tertile) was 1.84 and 1.42, respectively. Longitudinal changes in nutritional status as well as episodes of acute kidney injury attenuated the risk only modestly. These findings were consistent across subgroups.
CONCLUSIONS: eGFR change over time adds prognostic information to traditional mortality risk predictors among patients with CKD. The utility of incorporating eGFR trends into patient-risk assessment should be further investigated.

Entities:  

Mesh:

Year:  2011        PMID: 21685022      PMCID: PMC3359538          DOI: 10.2215/CJN.00470111

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  18 in total

1.  K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2004-05       Impact factor: 8.860

2.  Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.

Authors:  Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

3.  Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.

Authors:  Adeera Levin; Ognjenka Djurdjev; Monica Beaulieu; Lee Er
Journal:  Am J Kidney Dis       Date:  2008-10       Impact factor: 8.860

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 5.  Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.

Authors:  Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt
Journal:  Clin Chem       Date:  2005-12-06       Impact factor: 8.327

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

8.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

Authors:  Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Rapid kidney function decline and mortality risk in older adults.

Authors:  Dena E Rifkin; Michael G Shlipak; Ronit Katz; Linda F Fried; David Siscovick; Michel Chonchol; Anne B Newman; Mark J Sarnak
Journal:  Arch Intern Med       Date:  2008-11-10
View more
  55 in total

Review 1.  Nondialysis chronic kidney disease in 2011: Progression, prediction, populations and possibilities.

Authors:  Adeera Levin
Journal:  Nat Rev Nephrol       Date:  2011-12-06       Impact factor: 28.314

2.  Improvement in kidney function: a real occurrence.

Authors:  Tanvir Chowdhury Turin; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 10.121

3.  Past Decline Versus Current eGFR and Subsequent Mortality Risk.

Authors:  David M J Naimark; Morgan E Grams; Kunihiro Matsushita; Corri Black; Iefke Drion; Caroline S Fox; Lesley A Inker; Areef Ishani; Sun Ha Jee; Akihiko Kitamura; Janice P Lea; Joseph Nally; Carmen Alicia Peralta; Dietrich Rothenbacher; Seungho Ryu; Marcello Tonelli; Hiroshi Yatsuya; Josef Coresh; Ron T Gansevoort; David G Warnock; Mark Woodward; Paul E de Jong
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

4.  Rate of change in renal function and mortality in elderly treated hypertensive patients.

Authors:  Enayet K Chowdhury; Robyn G Langham; Zanfina Ademi; Alice Owen; Henry Krum; Lindon M H Wing; Mark R Nelson; Christopher M Reid
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 8.237

Review 5.  Analytic Considerations for Repeated Measures of eGFR in Cohort Studies of CKD.

Authors:  Haochang Shou; Jesse Y Hsu; Dawei Xie; Wei Yang; Jason Roy; Amanda H Anderson; J Richard Landis; Harold I Feldman; Afshin Parsa; Christopher Jepson
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-27       Impact factor: 8.237

6.  Predicting outcomes of chronic kidney disease from EMR data based on Random Forest Regression.

Authors:  Jing Zhao; Shaopeng Gu; Adam McDermaid
Journal:  Math Biosci       Date:  2019-02-12       Impact factor: 2.144

7.  Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality.

Authors:  Casey M Rebholz; Morgan E Grams; Kunihiro Matsushita; Lesley A Inker; Meredith C Foster; Andrew S Levey; Elizabeth Selvin; Josef Coresh
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

8.  Past Decline Versus Current eGFR and Subsequent ESRD Risk.

Authors:  Csaba P Kovesdy; Josef Coresh; Shoshana H Ballew; Mark Woodward; Adeera Levin; David M J Naimark; Joseph Nally; Dietrich Rothenbacher; Benedicte Stengel; Kunitoshi Iseki; Kunihiro Matsushita; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

9.  The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Alokananda Ghosh; Mahboob Rahman; Paula T Einhorn; William C Cushman; Paul K Whelton; Jackson T Wright
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

10.  Fast GFR decline and progression to CKD among primary care patients with preserved GFR.

Authors:  Farrukh M Koraishy; Denise Hooks-Anderson; Joanne Salas; Michael Rauchman; Jeffrey F Scherrer
Journal:  Int Urol Nephrol       Date:  2018-02-05       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.